Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of goods sold | 12,512 | 11,898 | 23,086 | 20,626 |
| Research and development | 10,669 | 8,055 | 19,452 | 15,808 |
| Selling, general and administrative | 61,035 | 44,393 | 114,179 | 88,411 |
| Amortization of intangible assets | 2,711 | 2,711 | 5,421 | 5,421 |
| Total costs and expenses | 86,927 | 67,057 | 162,138 | 130,266 |
| Income from operations | 5,173 | 4,482 | 13,089 | 1,392 |
| Other income (expense): | ||||
| Interest and other income | 1,455 | 948 | 2,657 | 2,123 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s D&A?
- Xeris Biopharma Holdings, Inc. (XERS) reported D&A of $2.71M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s D&A changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s D&A decreased by 0.0% year-over-year, from $2.71M to $2.71M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s D&A?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s D&A has grown at a 110.7% compound annual growth rate (CAGR), from $550K to $10.84M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Xeris Biopharma Holdings, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude